The American Society of Hematology (ASH) will hold its 55th annual meeting in New Orleans, LA, December 7-10, 2013. The American Journal of Managed Care will be sending daily e-mail blasts with full conference coverage. Sign up on ourregistration page
, and check back here during the conference for all of our coverage!
In Treating Older CLL Patients, Cost Considerations Are a Factor
New therapies to treat chronic lymphocytic leukemia (CLL) will receive plenty of attention this week at the 55th American Society of Hematology Annual Meeting and Exposition in New Orleans. At an education session that opened the meeting Saturday, a physician with the Mayo Clinic made it clear that cost considerations are a reality for many older patients.
Treating the Signs of Multiple Myeloma Before it Starts
Progress in treating multiple myeloma, or cancer of the plasma cells in bone marrow, has advanced significantly over the past decade. Today, questions about the disease often involve finding a treatment that balances the goal of putting a patient into remission – especially if stem cell transplantation is a possibility – against the toxicity of the treatment itself.
Can Genetics Help Unlock the Mysteries Surrounding Adult ALL?
In recent years, overall progress in treating acute lymphoblastic leukemia (ALL), in which malignant white cells multiply in the bone marrow, has been tempered by this fact: Survival rates among children far outstrip those of adults, with childhood rates reaching 85% and adults registering at 45%.
Rituximab, Other Antibodies Offer Hope In Advancing ALL Treatment
Taking aim at relapse rates and overall poor outcomes among adult patients with acute lymphoblastic leukemia (ALL) demands both new therapies and new ways of thinking, according to Anjali S. Advani, MD, of the Cleveland Clinic. Antibodies, which have produced success in treating other blood cancers, offer promise because in some cases the same antigens are involved.